UCB announced that it has made available an oral solution formulation of Vimpat (lacosamide), an antiepileptic drug for the add-on treatment of partial-onset seizures in patients ≥17 years of age with epilepsy. Healthcare providers can convert patients between the already available tablet and intravenous injection formulations with equivalent dosing and without titration.

Vimpat is a C-V controlled substance. Vimpat oral solution is available in a 10mg/mL dosage strength.

For more information call (800) 477-7877 or visit www.vimpat.com.